drugset / Trial / NCT04338243
Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors
NaSingle-groupOpen-labelTreatment
Summary
To explore the safety and efficacy of Glumetinib combined with Osimertinib in the treatment of relapsed and metastatic non-small cell lung cancer (NSCLC) with failed first-generation or second-generation EGFR inhibitors, negative T790M mutation and met amplification.
Timeline
- Start
- 2019-11-18
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gumarontinib | Small molecule | 300 mg | Oral |
| Subject | Gumarontinib | Small molecule | 400 mg | Oral |
Indications
No indication recorded.